Free Trial
OTCMKTS:MKKGY

Merck KGaA Q4 2025 Earnings Report

Merck KGaA logo
$30.91 -0.06 (-0.19%)
As of 01:28 PM Eastern

Merck KGaA EPS Results

Actual EPS
$0.28
Consensus EPS
$0.47
Beat/Miss
Missed by -$0.19
One Year Ago EPS
N/A

Merck KGaA Revenue Results

Actual Revenue
$6.11 billion
Expected Revenue
$6.20 billion
Beat/Miss
Missed by -$93.46 million
YoY Revenue Growth
N/A

Merck KGaA Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Merck KGaA's next earnings date is estimated for Thursday, August 6, 2026, based on past reporting schedules.

Conference Call Resources

Merck KGaA Earnings Headlines

Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillion in stored capital will be looking for a home when it does. But the real opportunity isn't the IPO itself. Jovine has identified a small-cap supplier trading near $4 that sits directly in the path of xAI's Colossus infrastructure buildout - and a specific trigger in the S-1 could reprice it overnight.tc pixel
Merck KGaA (MKKGY) Q1 2026 Earnings Call Transcript
See More Merck KGaA Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Merck KGaA? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Merck KGaA and other key companies, straight to your email.

About Merck KGaA

Merck KGaA (OTCMKTS:MKKGY), Darmstadt, Germany, commonly referred to as Merck Group, is a multinational science and technology company with origins dating back to 1668. The company develops and manufactures products and technologies across healthcare, life science and electronics applications. It is distinct from the U.S. pharmaceutical company Merck & Co.; Merck KGaA is a European group headquartered in Darmstadt and is publicly listed in Germany with an OTC American depositary receipt available under the symbol MKKGY.

Merck’s Healthcare business develops prescription medicines and related services focused on areas such as oncology, immunology, neurology (including therapies for multiple sclerosis) and fertility. The Life Science division supplies reagents, lab consumables, filtration and chromatography solutions, and bioprocessing technologies to research institutions and biopharmaceutical manufacturers — operations that include the MilliporeSigma brand in the United States and Canada following the acquisition of Sigma‑Aldrich. The Electronics business produces high‑performance materials and specialty chemicals used in semiconductor fabrication, display technologies and other advanced industrial applications.

The company operates globally, serving customers across Europe, the Americas, Asia and other regions through manufacturing sites, research centers and commercial affiliates. Since May 2021 Merck KGaA has been led by Chair of the Executive Board and CEO Belén Garijo. Merck emphasizes integrated R&D and partnerships to support pharmaceutical development, laboratory science and materials innovation, positioning itself as a diversified supplier to healthcare, research and high‑technology industries.

View Merck KGaA Profile